Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MTB004
MIFTS: 50

Metabolic Acidosis

Categories: Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Metabolic Acidosis

About this section

MalaCards integrated aliases for Metabolic Acidosis:

Name: Metabolic Acidosis 12 74 29 54 6 15 71

Classifications:

MalaCards categories:
Global: Metabolic diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050758
UMLS 71 C0220981
Sources

Summaries for Metabolic Acidosis

About this section
Disease Ontology : 12 An acquired metabolic disease that characterized by excessive production of acid.

MalaCards based summary : Metabolic Acidosis is related to distal renal tubular acidosis and renal tubular acidosis, distal, autosomal recessive. An important gene associated with Metabolic Acidosis is ATP6V1B1 (ATPase H+ Transporting V1 Subunit B1), and among its related pathways/superpathways are Metabolism and Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds. The drugs Insulin glulisine and Tramadol have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Metabolic acidosis is a disorder that occurs when the body produces excessive amounts of acid, such as... more...

Sources

Related Diseases for Metabolic Acidosis

About this section

Diseases related to Metabolic Acidosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 410)
# Related Disease Score Top Affiliating Genes
1 distal renal tubular acidosis 33.4 SLC4A1 CA2 ATP6V1B1 ATP6V0A4
2 renal tubular acidosis, distal, autosomal recessive 32.7 SLC4A1 ATP6V1B1 ATP6V0A4
3 renal tubular acidosis 32.7 SLC9A3 SLC4A4 SLC4A1 CA2 ATP6V1B1 ATP6V0A4
4 medullary sponge kidney 30.5 ATP6V1B1 ATP6V0A4
5 arthrogryposis, distal, type 3 30.4 WNK4 WNK1
6 autosomal recessive disease 30.4 MLYCD HMGCL GLS ATP6V1B1 ATP6V0A4
7 nephrocalcinosis 30.4 SLC4A1 CA2 ATP6V1B1 ATP6V0A4 ALB
8 pseudohypoaldosteronism 30.4 WNK4 WNK1 KLHL3
9 nephrolithiasis, calcium oxalate 30.2 SLC9A3 SLC4A1 BGLAP ATP6V1B1 ATP6V0A4 AQP2
10 primary biliary cirrhosis 29.7 OGDH CA2 BGLAP ALB
11 meconium ileus 29.5 SLC9A3 SLC4A4
12 hypertension, essential 29.3 WNK4 WNK1 SLC9A3 SLC9A1 SLC4A4 KLHL3
13 ovarian dysgenesis, hypergonadotropic, with short stature and recurrent metabolic acidosis 12.5
14 glutathione synthetase deficiency 11.8
15 3-hydroxy-3-methylglutaryl-coa lyase deficiency 11.8
16 fructose-1,6-bisphosphatase deficiency 11.7
17 lactic acidosis 11.7
18 multiple acyl-coa dehydrogenase deficiency 11.7
19 hawkinsinuria 11.7
20 carbonic anhydrase va deficiency, hyperammonemia due to 11.6
21 d-glyceric aciduria 11.6
22 pseudohypoaldosteronism, type iie 11.5
23 hypoaldosteronism 11.5
24 renal tubular acidosis, proximal 11.4
25 lowe oculocerebrorenal syndrome 11.4
26 renal tubular acidosis, distal, with progressive nerve deafness 11.4
27 renal tubular acidosis, distal, autosomal dominant 11.3
28 leigh syndrome, french canadian type 11.3
29 malonyl-coa decarboxylase deficiency 11.3
30 3-methylglutaconic aciduria, type i 11.3
31 pseudohypoaldosteronism, type i, autosomal recessive 11.3
32 fumarase deficiency 11.3
33 mitochondrial trifunctional protein deficiency 11.3
34 slc4a1-associated distal renal tubular acidosis 11.3
35 malignant hyperthermia 1 11.3
36 holocarboxylase synthetase deficiency 11.3
37 mitochondrial dna depletion syndrome 6 11.3
38 mitochondrial complex i deficiency, nuclear type 20 11.3
39 renal tubular acidosis, distal, with hemolytic anemia 11.3
40 pseudohypoaldosteronism, type iid 11.3
41 carbonic anhydrase va deficiency 11.3
42 corticosterone methyloxidase deficiency 11.3
43 pseudohypoaldosteronism, type iia 11.1
44 arthrogryposis, renal dysfunction, and cholestasis 1 11.1
45 cranioectodermal dysplasia 1 11.1
46 hydroxykynureninuria 11.1
47 isovaleric acidemia 11.1
48 methylmalonyl-coa epimerase deficiency 11.1
49 mitochondrial myopathy with lactic acidosis 11.1
50 pyruvate carboxylase deficiency 11.1

Graphical network of the top 20 diseases related to Metabolic Acidosis:



Diseases related to Metabolic Acidosis
Sources

Symptoms & Phenotypes for Metabolic Acidosis

About this section

GenomeRNAi Phenotypes related to Metabolic Acidosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.07 WNK4
2 Decreased viability GR00221-A-2 10.07 WNK4
3 Decreased viability GR00221-A-3 10.07 WNK1
4 Decreased viability GR00221-A-4 10.07 WNK1 WNK4
5 Decreased viability GR00381-A-1 10.07 MLYCD
6 Decreased viability GR00402-S-2 10.07 ALB AQP2 ATP6V0A4 ATP6V1B1 BGLAP CA2
7 no effect GR00402-S-1 9.62 ALB AQP2 ATP6V0A4 ATP6V1B1 BGLAP CA2

MGI Mouse Phenotypes related to Metabolic Acidosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.9 ALB ATP6V1B1 HMGCL KLHL3 MLYCD SLC4A1
2 homeostasis/metabolism MP:0005376 9.83 ALB AQP2 ATP6V0A4 ATP6V1B1 CA2 FBP1
3 renal/urinary system MP:0005367 9.36 ALB AQP2 ATP6V0A4 ATP6V1B1 CA2 KLHL3
Sources

Drugs & Therapeutics for Metabolic Acidosis

About this section

Drugs for Metabolic Acidosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Insulin glulisine Approved Phase 4 207748-29-6
2
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Nefopam Approved, Investigational Phase 4 13669-70-0
5
Clonidine Approved Phase 4 4205-90-7 2803
6
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
7
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
8
Potassium citrate Approved, Investigational, Vet_approved Phase 4
9
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
10
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
11
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
12
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
13
Dobutamine Approved Phase 4 34368-04-2 36811
14
Racepinephrine Approved Phase 4 329-65-7 838
15
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
16
Sodium citrate Approved, Investigational Phase 4 68-04-2
17
tannic acid Approved Phase 4 1401-55-4
18
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
19
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
20
Zinc Approved, Investigational Phase 4 7440-66-6 32051
21
Insulin aspart Approved Phase 4 116094-23-6 16132418
22
carbamide peroxide Approved Phase 4 124-43-6
23
Norepinephrine Approved Phase 4 51-41-2 439260
24
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
25
Phenylephrine Approved Phase 4 59-42-7 6041
26
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
27
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
28
Ethanol Approved Phase 4 64-17-5 702
29
Lorazepam Approved Phase 4 846-49-1 3958
30
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
31
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
32
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
33
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
34
Simendan Investigational Phase 4 131741-08-7
35 Anesthetics, Intravenous Phase 4
36 Calamus Phase 4
37 Insulin, Short-Acting Phase 4
38 Anesthetics, Local Phase 4
39 Narcotics Phase 4
40 Antipyretics Phase 4
41 Adjuvants, Anesthesia Phase 4
42 Analgesics, Opioid Phase 4
43 Antioxidants Phase 4
44 Protective Agents Phase 4
45 Dialysis Solutions Phase 4
46 Anticoagulants Phase 4
47 Chelating Agents Phase 4
48 Calcium, Dietary Phase 4
49 Expectorants Phase 4
50 calcium heparin Phase 4

Interventional clinical trials:

(show top 50) (show all 195)
# Name Status NCT ID Phase Drugs
1 Comparison of Plasmalyte A, Normal Saline and Ringer Lactate as Intraoperative Fluids in Patients Undergoing Renal Transplantation. Unknown status NCT03115060 Phase 4 intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE
2 Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients. Unknown status NCT01228292 Phase 4 Unfractionated heparin;Citrasate
3 Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy Unknown status NCT03112538 Phase 4 Multiple daily injections of insulin
4 Comparing Heated Humidified High-flow Nasal Cannula Therapy and Nasal Continuous Positive Airway Pressure (nCPAP) Ventilation Methods for the Prevention of Extubation Failure in Preterm Infants Less Than 32 Weeks' Gestational Age: Randomized Clinical Trial Unknown status NCT02887846 Phase 4
5 A MULTICENTER, RANDOMIZED, CONTROLLED STUDY OF EPIDURAL ANALGESIA FOR SEVERE ACUTE PANCREATITIS Unknown status NCT02126332 Phase 4
6 Randomized Controlled Trial of Intravenous Fluid In Severely Injured Paediatric Trauma Patients: Comparison of Normal Saline Versus Ringer's Lactate Completed NCT01692769 Phase 4 Normal Saline;Ringer's Lactate
7 Supportive Measures in Treatment of Aluminum Phosphide Poisoning as a Trial to Reduce Mortality at Assiut University Hospital Completed NCT03879356 Phase 4 N-acetyl cysteine
8 Effect of Oral Vitamin C on The Inflammatory Biomarkers in Hemodialysis Completed NCT01356433 Phase 4 oral vitamin C;oral vitamin C
9 Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Renal Failure: a Randomized Controlled Trial Completed NCT01269112 Phase 4
10 A Feasibility Randomised Controlled Trial: Effects of Oral Sodium Bicarbonate Supplementation in Patients on Haemodialysis Completed NCT02692378 Phase 4 sodium bicarbonate 500mg capsules
11 Assessing the Safety of a Continuous Potassium Chloride Infusion in Critical Care: A Randomised Controlled Trial Completed NCT00718068 Phase 4 Sterile Potassium Chloride Concentrate;Sterile Potassium Chloride Concentrate
12 Randomized, Long-Term Administration of pH-Neutral PD Solutions Containing Lactate (BALANCE) or Bicarbonate (BICAVERA) in Children Completed NCT01632046 Phase 4 lactate and bicarbonate buffered dialysis solutions
13 The Effects of Levosimendan on Renal Function in Patients With Low Ejection Fraction Undergoing Mitral Valve Surgery. Completed NCT01969071 Phase 4 Levosimendan;Dobutamine
14 A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia Completed NCT00357331 Phase 4 potassium citrate
15 Effect of Arterial pH on N-balances of Patients Undergoing Automated Peritoneal Dialysis Completed NCT00586131 Phase 4 ammonium chloride or sodium citrate/citric acid;Sodium citrate/citratic acid
16 High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy: a Pragmatic Randomized Control Trial Recruiting NCT03846258 Phase 4 Low bicarbonate solution (22 mmol/L);High Bicarbonate solution (32 mmol/L)
17 Prospective Evaluation of Oral Alkalinization by Urologists and Nephrologists: Evolution of the Extracellular Compartment Recruiting NCT03035812 Phase 4 Alkali
18 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion, in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Peritonitis. Recruiting NCT03771170 Phase 4 Rheosorbilact®;Ringer lactate
19 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion, in Comparison With Ringer's Lactate, Solution for Infusion, in a Complex Therapy of Sepsis. Recruiting NCT03764085 Phase 4 Rheosorbilact®;Ringer lactate
20 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion ("Yuria-Pharm"), in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Pneumonia. Recruiting NCT03824457 Phase 4 Rheosorbilact®;Ringer lactate
21 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion ("Yuria-Pharm"), in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Burns Recruiting NCT04152096 Phase 4 Rheosorbilact®;Ringer lactate
22 Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane Recruiting NCT03384563 Phase 4 Dexmedetomidine
23 Impact of Early CRRT Intervention in Patients Receiving VA-ECMO Support on 30-day Mortality: A Randomized Controlled Trial Recruiting NCT03549923 Phase 4 Esmolol;Standard care
24 Preservation of Kidney Function in Kidney Transplant Recipients by Alkali Therapy (Preserve-Transplant Study): a Multi-center Randomized Single-blind Placebo- Controlled Trial Active, not recruiting NCT03102996 Phase 4 Nephrotrans
25 InSaKa Trial: Insulin Dextrose Infusion Versus Nebulized Salbutamol Versus Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia: a Randomized Clinical Trial Not yet recruiting NCT04012138 Phase 4 Salbutamol;Insulin Aspart
26 A Single-center Randomized Double Blinded Control Trial of Intravenous Fluid Content in Children With Diabetic Ketoacidosis Admitted to the Pediatric Intensive Care Unit Suspended NCT03066440 Phase 4 Normal saline;Lactated Ringers
27 A Double-Blind, Randomized, Comparative Efficacy and Safety Trial of Intravenous Solutions for the Treatment of Moderate to Severe Dehydration in Children With Acute Gastroenteritis Terminated NCT01234883 Phase 4 multiple electrolyte solution;saline
28 Randomized, Multicenter Cross-over Study in Investigating the Effect of Bicarbonate-based Solutions (Physioneal 35 vs. 40) on Protein Metabolism in Children and Adolescents on Chronic Peritoneal Dialysis Terminated NCT00776191 Phase 4 Physioneal 35;Physioneal 40
29 Perioperative Fluid Management in Patients Receiving Major Abdominal Surgery - Effects of Normal Saline Versus an Acetate Buffered Balanced Infusion Solution on the Necessity of Catecholamines for Cardiocirculatory Support, a Randomized Controlled Double-blind Trial Terminated NCT02414555 Phase 4 vasopressor;fluid bolus;Normal Saline;Elo-Mel Isoton (balanced acetat-based infusate)
30 Forced Fluid Removal vs. Usual Intensive Care in High-risk Acute Kidney Injury With Severe Fluid Overload - A Randomized Controlled Trial Terminated NCT02458157 Phase 4 Furosemide (Furix)
31 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos
32 A Prospective, Controlled, Randomized, Multicentric Study: Correction of Metabolic Acidosis With Use of Bicarbonate in Chronic Renal Insufficiency (CKD3b-4) Unknown status NCT01640119 Phase 3
33 Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill : A Multiple Center Randomized Clinical Trial (BICAR-ICU) Unknown status NCT02476253 Phase 3 Sodium Bicarbonate
34 Comparative Analysis Between Ringer's Lactate vs Acetate Containing Balanced Crystalloid Solution (Plasma Lyte-A) as Cardiopulmonary Bypass Prime Unknown status NCT03043131 Phase 3 Plasmalyte A;Ringer Lactate
35 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis Completed NCT03317444 Phase 3 TRC101;Placebo
36 A Blinded, Placebo-Controlled Extension to Study TRCA-301 to Evaluate the Long-term Safety and Durability of Effect of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis Completed NCT03390842 Phase 3 TRC101;Placebo
37 Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects Completed NCT00888290 Phase 2, Phase 3 Sodium bicarbonate
38 Clearance of Acetate During Fluid Resuscitation of Critically Ill Burn Patients: The CARE Trial. Completed NCT03118362 Phase 3 Plasmalyte;Ringer lactate
39 Effect of Neutralization of Endogenous Acid Production on Bone Mineral Density and Microarchitectural Composition of Bone in Humans Completed NCT00509405 Phase 3 potassium citrate
40 Balanced Salt Solution Versus Normal Saline Solution During Initial Resuscitation in Severe Sepsis or Septic Shock Children: A Randomized Controlled Trial Completed NCT02336620 Phase 3 Ringer acetate;Normal saline
41 Study of Metformin HCL in Patients With Type 2 Diabetes Intensively Treated With Insulin: a Treatment Strategy for Insulin Resistance in Type 2 Diabetes Mellitus: a Randomized Controlled Trial Completed NCT00375388 Phase 3 Metformin on top of intensive insulin therapy
42 The Clinical Efficacy and Safety of a Proprietary Solution Containing Hypertonic Sodium Lactate (Totilac®) Infusion for Resuscitation of Patients With Hemorrhagic Shock Due to Multiple Injuries Completed NCT01433276 Phase 3 Hyperosmolar sodium lactate;Ringer's lactate
43 Efficacy of Albumin Administration for Volume Replacement in Patients With Severe Sepsis or Septic Shock - the ALBumin Italian Outcome Sepsis (ALBIOS) Study Completed NCT00707122 Phase 3
44 A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis Recruiting NCT03710291 Phase 3 TRC101;Placebo
45 A Phase 3B Open-Label Extension Of Study B23CS (ARENA 2) Evaluating The Continued Safety And Efficacy Of ADV7103 In Subjects With Primary Distal Renal Tubular Acidosis Recruiting NCT03831152 Phase 3 ADV7103
46 The Effect of Fluid Resuscitation With 0.9% Sodium Chloride Versus Balanced Crystalloid Solution on Renal Function of Sepsis Patients Recruiting NCT03277677 Phase 3 Normal saline;Ringer's Acetate
47 A Phase 3 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Withdrawal Study Evaluating ADV7103 In Pediatric and Adult Subjects With Distal Renal Tubular Acidosis (dRTA) Recruiting NCT03644706 Phase 3 ADV7103;Placebos
48 A Randomized, Open Label, Active Control, 2 Parallel Groups, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Balanced Salt Solution Versus 0.9% Saline in Patients With High Risk of Contrast Induced Nephropathy. Recruiting NCT02799368 Phase 3 CJ Plasma Solution A Injection;CJ 0.9% Normal Saline Injection
49 An Investigator-initiated, Pragmatic, Registry-based, Multi-centre, Double-blind, Randomised Controlled Trial Evaluating the Effect of Plasmalyte Versus 0.9% Saline on Early Kidney Transplant Function in Deceased Donor Kidney Transplantation Recruiting NCT03829488 Phase 3 Plasma-Lyte 148 (approx. pH 7.4) IV Infusion;0.9% SODIUM CHLORIDE 9g/L injection BP
50 Impact on Mortality of the Timing of Renal Replacement Therapy in Patients With Severe Acute Kidney Injury in Septic Shock: the IDEAL-ICU Study (Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit): Study Protocol for a Randomized Controlled Trial Terminated NCT01682590 Phase 3

Search NIH Clinical Center for Metabolic Acidosis

Sources

Genetic Tests for Metabolic Acidosis

About this section

Genetic tests related to Metabolic Acidosis:

# Genetic test Affiliating Genes
1 Metabolic Acidosis 29
Sources

Anatomical Context for Metabolic Acidosis

About this section

MalaCards organs/tissues related to Metabolic Acidosis:

40
Kidney, Liver, Bone, Heart, Brain, Lung, Testes
Sources

Publications for Metabolic Acidosis

About this section

Articles related to Metabolic Acidosis:

(show top 50) (show all 11083)
# Title Authors PMID Year
1
Band 3 Edmonton I, a novel mutant of the anion exchanger 1 causing spherocytosis and distal renal tubular acidosis. 54 61
20028337 2010
2
[Late onset 3-HMG-CoA lyase deficiency: a rare but treatable disorder]. 54 61
19932602 2010
3
Metabolic acidosis in patients with severe sepsis and septic shock: a longitudinal quantitative study. 54 61
19885998 2009
4
[Diagnosis, treatment and gene mutation analysis in children with holocarboxylase synthetas deficiency]. 54 61
19695181 2009
5
Albumin versus normal saline for dehydrated term infants with metabolic acidosis due to acute diarrhea. 54 61
19158801 2009
6
Equivalent metabolic acidosis with four colloids and saline on ex vivo haemodilution. 54 61
19499860 2009
7
Acute and chronic metabolic acidosis interferes with aquaporin-2 translocation in the rat kidney collecting ducts. 54 61
19300448 2009
8
Correction of metabolic acidosis on serum albumin and protein catabolism in hemodialysis patients. 54 61
19218045 2009
9
Risk factors in patients surgically treated for peptic ulcer perforation. 54 61
18785067 2009
10
[Ethylene glycol intoxication. Important differential diagnosis in comatose patients with metabolic acidosis]. 54 61
18958433 2009
11
Anion gap, anion gap corrected for albumin, base deficit and unmeasured anions in critically ill patients: implications on the assessment of metabolic acidosis and the diagnosis of hyperlactatemia. 54 61
19087326 2008
12
[Case of severe streptococcus pyogenes pneumonia with streptococcus toxic shock syndrome]. 54 61
18592996 2008
13
Poisoning with 1-propanol and 2-propanol. 54 61
18375643 2007
14
Profound metabolic acidosis and oxoprolinuria in an adult. 54 61
18072147 2007
15
Distal renal tubular acidosis associated with anion exchanger 1 mutations in children in Thailand. 54 61
17533027 2007
16
Inborn errors in the metabolism of glutathione. 54 61
17397529 2007
17
Chronic metabolic acidosis alters osteoblast differentiation from human mesenchymal stem cells. 54 61
17183249 2007
18
Long-term oral sodium bicarbonate supplementation does not improve serum albumin levels in hemodialysis patients. 54 61
17409769 2007
19
Role of deadenylation and AUF1 binding in the pH-responsive stabilization of glutaminase mRNA. 54 61
16219914 2006
20
Holocarboxylase synthetase deficiency presenting as ichthyosis. 54 61
16650223 2006
21
The anion gap (AG): studies in the nephrotic syndrome and diabetic ketoacidosis (DKA). 54 61
16503241 2006
22
Brain abnormalities in a case of malonyl-CoA decarboxylase deficiency. 54 61
16275149 2006
23
Localization of NBC1 variants in rat kidney. 54 61
16785749 2006
24
[Serum creatine kinase activity in dogs and cats with metabolic diseases]. 54 61
16240913 2005
25
Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. 54 61
15957126 2005
26
Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. 54 61
15771438 2005
27
Predictors of multi-organ dysfunction in heatstroke. 54 61
15735266 2005
28
Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. 54 61
15712076 2005
29
[Factors predisposing to malnutrition development in the patients on maintenance hemodialysis]. 54 61
16334531 2005
30
Acid-base balance may influence risk for insulin resistance syndrome by modulating cortisol output. 54 61
15607573 2005
31
[Gluthathion synthetase deficit in a newborn infant]. 54 61
15519833 2004
32
Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). 54 61
15384017 2004
33
Is an intravenous fluid bolus of albumin or normal saline beneficial in the treatment of metabolic acidosis in a normovolaemic newborn? 54 61
15321875 2004
34
Regulation of aquaporin-2 by metabolic acidosis. 54 61
15308467 2004
35
[The short term prognosis in alcoholic liver disease with metabolic acidosis]. 54 61
15218345 2004
36
Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression. 54 61
15016134 2004
37
Coordinated increase in albumin, fibrinogen, and muscle protein synthesis during hemodialysis: role of cytokines. 54 61
14722024 2004
38
A novel nonsense mutation of the mineralocorticoid receptor gene in a Swedish family with pseudohypoaldosteronism type I (PHA1). 54 61
14715854 2004
39
Successful orthotopic liver transplantation after trimethoprim-sulfamethoxazole associated fulminant liver failure. 54 61
14703931 2003
40
[Nephrogenic metabolic acidosis]. 54 61
12908170 2003
41
Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. 54 61
12515852 2003
42
Mechanisms of bilirubin toxicity: clinical implications. 54 61
12516745 2002
43
[Severe ethylene glycol poisoning treated wtih fomepizole (4-methylpyrazole)]. 54 61
12448112 2002
44
Pyruvate carboxylase deficiency--insights from liver transplantation. 54 61
12359142 2002
45
Systemic pseudohypoaldosteronism from deletion of the promoter region of the human Beta epithelial na(+) channel subunit. 54 61
12204893 2002
46
Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients. 54 61
11917058 2002
47
[Hyperchloremic acidosis druing plasma volume replacement]. 54 61
11963385 2002
48
The role of endothelin in proximal tubule proton secretion and the adaptation to a chronic metabolic acidosis. 54 61
12027224 2002
49
[Role of the Na(+)-K+(NH4+)-2Cl cotransporter of the medullary ascending limb in the regulation of renal acid-base equilibrium]. 54 61
12227253 2002
50
Acute metabolic acidosis decreases muscle protein synthesis but not albumin synthesis in humans. 54 61
11728951 2001
Sources

Variations for Metabolic Acidosis

About this section

ClinVar genetic disease variations for Metabolic Acidosis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CA1 NM_001738.5(CA1):c.368_369del (p.His123fs)deletion Uncertain significance 694733 8:86245835-86245836 8:85333606-85333607
Sources

Expression for Metabolic Acidosis

About this section
Search GEO for disease gene expression data for Metabolic Acidosis.
Sources

Pathways for Metabolic Acidosis

About this section

Pathways related to Metabolic Acidosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Metabolism 65
Show member pathways
 13.79 SLC9A1 SLC4A1 OGDH MLYCD HMGCL GSS
2
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds 65
Show member pathways
 12.78 WNK4 WNK1 SLC9A3 SLC9A1 SLC4A4 SLC4A1
3
Ion channel transport 65
Show member pathways
 12.27 WNK4 WNK1 ATP6V1B1 ATP6V0A4
4
Glucose / Energy Metabolism 4
12.25 SLC4A4 FBP1 CA2 AQP2
5
Insulin receptor recycling 65
Show member pathways
 12.15 SLC4A1 CA2 ATP6V1B1 ATP6V0A4
6
Pancreatic secretion 36
11.62 SLC9A1 SLC4A4 CA2
7
Amino Acid metabolism 1
11.52 OGDH HMGCL GSS GLS
8
Bile secretion 36
11.31 SLC9A3 SLC9A1 SLC4A4 CA2
9
Proximal tubule bicarbonate reclamation 36
10.38 SLC9A3 SLC4A4 GLS2 GLS CA2
10
D-Glutamine and D-glutamate metabolism 36
Show member pathways
 10.21 GLS2 GLS
Sources

GO Terms for Metabolic Acidosis

About this section

Cellular components related to Metabolic Acidosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.87 SLC9A3 SLC9A1 SLC4A4 SLC4A1 CA2 ATP6V1B1
2 extracellular exosome GO:0070062 9.7 SLC9A3 SLC9A1 SLC4A4 SLC4A1 GSS FBP1
3 mitochondrial matrix GO:0005759 9.65 OGDH MLYCD HMGCL GLS2 GLS
4 apical plasma membrane GO:0016324 9.55 SLC9A3 SLC9A1 ATP6V1B1 ATP6V0A4 AQP2
5 vacuolar proton-transporting V-type ATPase complex GO:0016471 9.37 ATP6V1B1 ATP6V0A4
6 basolateral plasma membrane GO:0016323 9.1 SLC9A1 SLC4A4 SLC4A1 CA2 ATP6V1B1 AQP2

Biological processes related to Metabolic Acidosis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 sodium ion transport GO:0006814 9.79 SLC9A3 SLC9A1 SLC4A4
2 ossification GO:0001503 9.76 BGLAP ATP6V1B1 ATP6V0A4
3 ion transport GO:0006811 9.76 WNK4 WNK1 SLC9A3 SLC9A1 SLC4A4 SLC4A1
4 protein homotetramerization GO:0051289 9.75 GLS FBP1 AQP2
5 proton transmembrane transport GO:1902600 9.73 SLC9A3 SLC9A1 ATP6V1B1 ATP6V0A4
6 bicarbonate transport GO:0015701 9.67 SLC4A4 SLC4A1 CA2
7 anion transport GO:0006820 9.61 SLC4A4 SLC4A1
8 glutamine metabolic process GO:0006541 9.6 GLS2 GLS
9 sodium ion import across plasma membrane GO:0098719 9.59 SLC9A3 SLC9A1
10 positive regulation of sodium ion transmembrane transporter activity GO:2000651 9.57 WNK4 WNK1
11 positive regulation of ion transmembrane transporter activity GO:0032414 9.56 WNK4 WNK1
12 anion transmembrane transport GO:0098656 9.56 SLC9A3 SLC9A1 SLC4A4 SLC4A1
13 positive regulation of potassium ion import GO:1903288 9.55 WNK4 WNK1
14 negative regulation of sodium ion transport GO:0010766 9.54 WNK4 WNK1
15 negative regulation of pancreatic juice secretion GO:0090188 9.52 WNK4 WNK1
16 glutamate biosynthetic process GO:0006537 9.51 GLS2 GLS
17 ion homeostasis GO:0050801 9.5 WNK4 WNK1 KLHL3
18 renal sodium ion absorption GO:0070294 9.48 WNK4 KLHL3
19 glutamine catabolic process GO:0006543 9.46 GLS2 GLS
20 distal tubule morphogenesis GO:0072156 9.4 WNK4 KLHL3
21 regulation of cellular process GO:0050794 9.37 WNK4 WNK1
22 regulation of pH GO:0006885 9.26 SLC9A3 SLC9A1 ATP6V1B1 ATP6V0A4
23 regulation of intracellular pH GO:0051453 9.02 SLC9A3 SLC9A1 SLC4A4 SLC4A1 CA2

Molecular functions related to Metabolic Acidosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 solute:proton antiporter activity GO:0015299 9.43 SLC9A3 SLC9A1
2 anion transmembrane transporter activity GO:0008509 9.4 SLC4A4 SLC4A1
3 inorganic anion exchanger activity GO:0005452 9.37 SLC4A4 SLC4A1
4 sodium:proton antiporter activity GO:0015385 9.32 SLC9A3 SLC9A1
5 potassium:proton antiporter activity GO:0015386 9.26 SLC9A3 SLC9A1
6 chloride channel inhibitor activity GO:0019869 9.16 WNK4 WNK1
7 potassium channel inhibitor activity GO:0019870 8.96 WNK4 WNK1
8 glutaminase activity GO:0004359 8.62 GLS2 GLS
Sources

Sources for Metabolic Acidosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....